Biodexa Pharmaceuticals PLC announced the outcome of its re-scheduled Annual General Meeting held on June 30, 2026, where shareholders approved seven ordinary resolutions with significant majorities. The meeting, conducted at 11.00 BST, saw resolutions 1 through 7 pass with support ranging from 73% to 94%. However, ordinary resolution 8 and special resolution 10 did not secure the required votes to pass. Consequently, resolution 11, which was contingent on the passing of resolution 8, also failed to pass.

The voting results highlight shareholder approval on key corporate matters while rejecting specific proposals that required special or contingent approval. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The company's lead development programs include eRapa, MTX240, and tolimidone, targeting various conditions including Familial Adenomatous Polyposis, Non-Muscle Invasive Bladder Cancer, Gastrointestinal Stromal Tumors (GIST), and type 1 diabetes.

Voting Results Overview

The following table summarizes the voting outcomes for the resolutions presented at the Annual General Meeting:

Key Development Programs

Biodexa's pipeline focuses on addressing unmet medical needs through innovative treatments. eRapa, a proprietary oral capsule formulation of rapamycin, is under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer. MTX240, a molecular glue, targets Gastrointestinal Stromal Tumors (GIST) by inducing apoptosis in cancer cells. Tolimidone, an orally delivered inhibitor of Lyn kinase, is being developed for the treatment of type 1 diabetes, with potential as a first-in-class blood glucose modulating agent.

The company's headquarters and R&D facility are located in Cardiff, UK. Biodexa continues to advance its clinical-stage programs aimed at treating gastrointestinal cancers and other critical conditions.

Biodexa Pharmaceuticals PLC has received approval from Health Canada to expand its registrational Phase 3 Serenta trial for familial adenomatous polyposis (FAP) into Canada. The expansion aims to accelerate enrolment for the study, which targets a condition with no approved therapeutic options and where life-altering surgery remains the standard of care.

The Serenta trial is currently active in 29 recruiting clinical centers across the US and five European countries. Canada is expected to add three or four new centers to the study. The trial plans to enrol 168 patients, with 73 patients enrolled as of June 29, 2026.

Stephen Stamp, Chief Executive Officer of Biodexa, highlighted the recent acceleration in enrolment due to the opening of European centers. He noted that the addition of Canada supports the company's enrolment goals and that Serenta has been positively received by clinicians and FAP patients.

The Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas. The trial is a double-blind, placebo-controlled study designed to evaluate eRapa, a proprietary oral capsule formulation of rapamycin, which acts as an mTOR inhibitor.

Key Trial Details

About Familial Adenomatous Polyposis

FAP is characterized by the proliferation of polyps in the colon and/or rectum, typically occurring in the mid-teens. Without treatment, the condition usually leads to colorectal cancer. The incidence is reported as one in 5,000 to 10,000 in the US and one in 11,300 to 37,600 in Europe. eRapa has received Orphan Designation in the US, with plans to seek similar designation in Europe.